M&A Deal Summary

Premier Acquires TheraDoc

On August 5, 2014, Premier acquired information technology company TheraDoc from Hospira for 117M USD

Acquisition Highlights
  • This is Premier’s 2nd transaction in the Information Technology sector.
  • This is Premier’s 2nd largest (disclosed) transaction.
  • This is Premier’s 5th transaction in the United States.
  • This is Premier’s 2nd transaction in Utah.

M&A Deal Summary

Date 2014-08-05
Target TheraDoc
Sector Information Technology
Buyer(s) Premier
Sellers(s) Hospira
Deal Type Divestiture
Deal Value 117M USD

Target

TheraDoc

Salt Lake City, Utah, United States
TheraDoc, Inc. is a provider of electronic clinical surveillance to healthcare organizations. TheraDoc’s suite of software applications brings together disparate data from a hospital’s source systems, helps alert clinicians to potential risks, and empowers them with knowledge to improve clinical outcomes, lower costs, and strengthen regulatory compliance.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Premier

Charlotte, North Carolina, United States

Category Company
Founded 2013
Sector Information Technology
Employees2,800
Revenue 1.3B USD (2023)
DESCRIPTION
Entrance to Premier's corporate headquarters in Charlotte, North Carolina.
Entrance to Premier's corporate headquarters in Charlotte, North Carolina.

Premier is a healthcare improvement company, uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier delivers value through a comprehensive technology-enabled platform that offers supply chain services, clinical, financial, operational and population health software-as-a-service (SaaS) informatics products, advisory services and performance improvement collaborative programs. Premier was founded in 2013 and is based in Charlotte, North Carolina.


DEAL STATS #
Overall 5 of 17
Sector (Information Technology) 2 of 4
Type (Divestiture) 1 of 4
State (Utah) 2 of 2
Country (United States) 5 of 17
Year (2014) 2 of 3
Size (of disclosed) 2 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-07 MEMdata

College Station, Texas, United States

MEMdata LLC is a technology management company, provides equipment planning, sourcing and analytics business focused on capital equipment needs for existing medical facilities, as well as those under construction.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-29 Aperek

Raleigh, North Carolina, United States

Aperek, Inc. is a provider of web based analytics and savings solutions for the healthcare supply chain.

Buy $49M

Seller(S) 1

SELLER

Hospira

Lake Forest, Illinois, United States

Category Company
Founded 2003
Sector Life Science
Employees19,000
Revenue 4.5B USD (2014)
DESCRIPTION

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Hospira, Inc. is based in Lake Forest, Illinois.


DEAL STATS #
Overall 3 of 3
Sector (Information Technology) 1 of 1
Type (Divestiture) 3 of 3
State (Utah) 1 of 1
Country (United States) 2 of 2
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-01 Javelin Pharmaceuticals

Cambridge, Massachusetts, United States

Javelin Pharmaceuticals, Inc., headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The company has one marketed drug in the U.K., an NDA-submitted drug candidate, Dyloject, and two drug candidates in U.S. advanced clinical development.

Buy $145M